Advertisement

European Journal of Nutrition

, Volume 52, Issue 2, pp 717–726 | Cite as

Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women

  • Ángel A. López-González
  • Félix GrasesEmail author
  • Nieves Monroy
  • Bartolome Marí
  • Mª Teófila Vicente-Herrero
  • Fernando Tur
  • Joan Perelló
Original Contribution

Abstract

Introduction

The objective of this paper was to evaluate the relationship between urinary concentrations of InsP6, bone mass loss and risk fracture in postmenopausal women.

Materials and methods

A total of 157 postmenopausal women were included in the study: 70 had low (≤0.76 μM), 42 intermediate (0.76–1.42 μM) and 45 high (≥1.42 μM) urinary phytate concentrations. Densitometry values for neck were measured at enrollment and after 12 months (lumbar spine and femoral neck), and 10-year risk fracture was calculated using the tool FRAX®.

Results

Individuals with low InsP6 levels had significantly greater bone mass loss in the lumbar spine (3.08 ± 0.65 % vs. 0.43 ± 0.55 %) than did those with high phytate levels. Moreover, a significantly greater percentage of women with low than with high InsP6 levels showed more than 2 % of bone mass loss in the lumbar spine (55.6 vs. 20.7 %). The 10-year fracture probability was also significantly higher in the low-phytate group compared to the high-phytate group, both in hip (0.37 ± 0.06 % vs 0.18 ± 0.04 %) and major osteoporotic fracture (2.45 ± 0.24 % vs 1.83 ± 0.11 %).

Discussion

It can be concluded that high urinary phytate concentrations are correlated with reduced bone mass loss in lumbar spine over 12 months and with reduced 10-year probability of hip and major osteoporotic fracture, indicating that increased phytate consumption can prevent development of osteoporosis.

Keywords

Bone mass loss Bone mineral density Osteoporosis Phytate Risk of fracture 

Abbreviations

SERMs

Selective estrogen receptor modulators

FDA

US food and drug administration

RANKL

Receptor activator for nuclear factor κ B ligand

HRT

Hormone replacement therapy

InsP6

Myo-inositol hexaphosphate, phytate

HAP

Hydroxyapatite

BMD

Bone mineral density

Notes

Acknowledgments

F.T. thanks the Ministerio de Ciencia e Innovación de España for a Torres Quevedo contract. This work was supported by the Conselleria d’Innovacio i Energia del Govern de les Illes Balears and by project grant no. CTQ2010-18271 from the Ministerio de Ciencia y Tecnologia de España.

Conflict of interest

F.G. and J.P. declare that they are inventors of a pending patent application based on some aspects of this work. F.T. is employee at Laboratoris Sanifit. J.P. is employee and stockholder at Laboratoris Sanifit.

References

  1. 1.
    Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Comm Sci Advisors Int Osteoporos Int 11:92–202Google Scholar
  2. 2.
    Haralson RH, Zuckerman JD (2009) Prevalence, health care expenditures, and orthopedic surgery workforce musculoskeletal conditions. JAMA 302:1586–1587CrossRefGoogle Scholar
  3. 3.
    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefGoogle Scholar
  4. 4.
    Kawai M, Modder UI, Khosla S, Rosen CJ (2011) Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 10:141–156CrossRefGoogle Scholar
  5. 5.
    Adami S, Zamberlan N (1996) Adverse effects of bisphosphonates—a comparative review. Drug Saf 14:158–170CrossRefGoogle Scholar
  6. 6.
    Khosla S, Burr D, Cauley J, Dempster DW et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491CrossRefGoogle Scholar
  7. 7.
    Cummings SR, San Martin J, McClung MR, Siris ES et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefGoogle Scholar
  8. 8.
    Pak CYC, Sakhaee K, Adamshuet B, Piziak V et al (1995) Treatment of postmenopausal osteoporosis with slow-release sodium-fluoride. Ann Intern Med 123:401–408Google Scholar
  9. 9.
    Mamelle N, Dusan R, Martin JL, Prost A et al (1988) Risk-benefit ratio of sodium-fluoride treatment in primary vertebral osteoporosis. Lancet 2:361–365CrossRefGoogle Scholar
  10. 10.
    Quattrocchi E, Kourlas H (2004) Teriparatide: a review. Clin Ther 26:841–854CrossRefGoogle Scholar
  11. 11.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefGoogle Scholar
  12. 12.
    Lindsay R, Nieves J, Formica C, Henneman E et al (1997) Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 350:550–555CrossRefGoogle Scholar
  13. 13.
    Writing group for the women’s health initiative investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–333CrossRefGoogle Scholar
  14. 14.
    Meunier PJ, Roux C, Seeman E, Ortolani S et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468CrossRefGoogle Scholar
  15. 15.
    Grases F, Simonet BM, Prieto RM, March JG (2001) Variation of InsP4, InsP5 and InsP6 levels in tissues and biological fluids depending on dietary phytate. J Nutr Biochem 12:595–601CrossRefGoogle Scholar
  16. 16.
    Grases F, Simonet BM, Prieto RM, March JG (2001) Dietary phytate and mineral bioavailability. J Trace Elem Med Biol 15:221–228CrossRefGoogle Scholar
  17. 17.
    Grases F, Simonet BM, Prieto RM, March JG (2001) Phytate levels in diverse rat tissues: influence of dietary phytate. Br J Nutr 86:225–231CrossRefGoogle Scholar
  18. 18.
    Schlemmer U, Frolich W, Prieto RM, Grases F (2009) Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res 53:S330–S375CrossRefGoogle Scholar
  19. 19.
    Grases F, Isern B, Sanchis P, Perello J et al (2007) Phytate acts as an inhibitor in formation of renal calculi. Front Biosci 12:2580–2587CrossRefGoogle Scholar
  20. 20.
    Hawkins PT, Poyner DR, Jackson TR, Letcher AJ et al (1993) Inhibition of iron-catalyzed hydroxyl radical formation by inositol polyphosphates—a possible physiological-function for myo-inositol hexakisphosphate. Biochem J 294:929–934Google Scholar
  21. 21.
    Grases F, Sanchis P, Prieto RM, Perello J et al (2010) Effect of tetracalcium dimagnesium phytate on bone characteristics in ovariectomized rats. J Med Food 13:1301–1306CrossRefGoogle Scholar
  22. 22.
    Lopez-Gonzalez AA, Grases F, Roca P, Mari B et al (2008) Phytate (myo-inositol hexaphosphate) and risk factors for osteoporosis. J Med Food 11:747–752CrossRefGoogle Scholar
  23. 23.
    Lopez-Gonzalez AA, Grases F, Perello J, Tur F et al (2010) Phytate levels and bone parameters: a retrospective pilot clinical trial. Front Biosci (Elite Ed.) 2:1093–1098CrossRefGoogle Scholar
  24. 24.
    Shamsuddin AM, Von Fraunhofer JA (2007) Decreasing titratable acidity of foodstuff or beverage, e.g. nutrient-enriched drinks, used to treat and prevent degeneration of teeth and other bones, involves depositing inositol phosphate composition into foodstuff or beverage. Patent. WO2007103110-A2Google Scholar
  25. 25.
    Grases F, Perello J, Isern B, Prieto RM (2004) Determination of myo-inositol hexakisphosphate (phytate) in urine by inductively coupled plasma atomic emission spectrometry. Anal Chim Acta 510:41–43CrossRefGoogle Scholar
  26. 26.
    March JG, Simonet BM, Grases F (2001) Determination of phytic acid by gas chromatography-mass spectroscopy: application to biological samples. J Chromatogr B 757:247–255CrossRefGoogle Scholar
  27. 27.
    Grases F, Garcia-Gonzalez R, Torres JJ, Llobera A (1998) Effects of phytic acid on renal stone formation in rats. Scand J Urol Nephrol 32:261–265CrossRefGoogle Scholar
  28. 28.
    Conte A, Piza P, Garcia-Raja A, Grases F et al (1999) Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate). Arch Esp Urol 52:305–310Google Scholar
  29. 29.
    Grases F, March JG, Prieto RM, Simonet BM et al (2000) Urinary phytate in calcium oxalate stone formers and healthy people—dietary effects on phytate excretion. Scand J Urol Nephrol 34:162–164CrossRefGoogle Scholar
  30. 30.
    Grases F, Prieto RM, Simonet BM, March JG (2000) Phytate prevents tissue calcifications in female rats. BioFactors 1:171–177CrossRefGoogle Scholar
  31. 31.
    Curhan GC, Willett WC, Knight EL, Stampfer MJ (2004) Dietary factors and the risk of incident kidney stones in younger women—nurses’ health study II. Arch Intern Med 164:885–891CrossRefGoogle Scholar
  32. 32.
    Grases F, Sanchis P, Perello J, Isern B et al (2006) Phytate (myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Front Biosci 1:136–142CrossRefGoogle Scholar
  33. 33.
    Grases F, Sanchis P, Perello J, Isern B et al (2008) Phytate reduces age-related cardiovascular calcification. Front Biosci 13:7115–7122CrossRefGoogle Scholar
  34. 34.
    Grases F, Sanchis P, Perello J, Isern B et al (2007) Effect of crystallization inhibitors on vascular calcifications induced by vitamin D—a pilot study in Sprague-Dawley rats. Circ J 71:152–1156CrossRefGoogle Scholar
  35. 35.
    Grases F, Sanchis P, Costa-Bauza A, Bonnin O et al (2008) Phytate inhibits bovine pericardium calcification in vitro. Cardiovasc Pathol 17:139–145CrossRefGoogle Scholar
  36. 36.
    Grases F, Santiago C, Simonet BM, Costa-Bauza A (2003) Sialolithiasis: mechanism of calculi formation and etiologic factors. Clin Chim Acta 334:131–136CrossRefGoogle Scholar
  37. 37.
    Grases F, Perello J, Sanchis P, Isern B et al (2009) Anticalculus effect of a triclosan mouthwash containing phytate: a double-blind, randomized, three-period crossover trial. J Periodontal Res 44:616–621CrossRefGoogle Scholar
  38. 38.
    Millan A, Pavelkova M, Sohnel O, Grases F (1998) Inhibition of calcium oxalate monohydrate crystal growth in high and low ionic strength solutions. Crystal Res Tech 33:777–786CrossRefGoogle Scholar
  39. 39.
    Grases F, March JG (1991) Adsorption processes during crystalline growth—an analytical tool. Trends Analyt Chem 10:190–195CrossRefGoogle Scholar
  40. 40.
    Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97:2692–2696CrossRefGoogle Scholar
  41. 41.
    Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643–2658CrossRefGoogle Scholar
  42. 42.
    Russell RGG (2007) Bisphosphonates: mode of action and pharmacology. Pediatrics 119:S150–S162CrossRefGoogle Scholar
  43. 43.
    William NA, Marc DM (2010) Inositol hexakisphosphate inhibits mineralization of MC3T3-E1 osteoblast cultures. Bone 46:1100–1107CrossRefGoogle Scholar
  44. 44.
    Grases F, Simonet BM, Vucenik I, Prieto RM et al (2001) Absorption and excretion of orally administered inositol hexaphosphate (IP6 or phytate) in humans. BioFactors 15:53–61CrossRefGoogle Scholar
  45. 45.
    Grases F, Simonet BM, March JG, Prieto RM (2002) Inositol hexakisphosphate in urine: the relationship between oral intake and urinary excretion. BJU Int 85:138–142CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Ángel A. López-González
    • 1
  • Félix Grases
    • 2
    Email author
  • Nieves Monroy
    • 3
  • Bartolome Marí
    • 4
  • Mª Teófila Vicente-Herrero
    • 5
  • Fernando Tur
    • 2
  • Joan Perelló
    • 2
  1. 1.Servicio de Prevención de Riesgos Laborales de GESMA (Gestión Sanitaria de Mallorca)Palma de MallorcaSpain
  2. 2.Laboratory of Renal Lithiasis Research, Faculty of Sciences, University Institute of Health Sciences Research (IUNICS)University of Balearic IslandsPalma de MallorcaSpain
  3. 3.Servicio de Prevención de Riesgos LaboralesAdministración del Govern de les Illes BalearsIslas BalearesSpain
  4. 4.Servicio de Medicina del Deporte. Consell Insular de MallorcaBalearic IslandsSpain
  5. 5.Servicio Médico de CorreosValencia-CastellónSpain

Personalised recommendations